drugset / Trial / NCT02212587

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex

NCT02212587

Phase 1 Completed 10 enrolled Unity Health Toronto
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to determine if tobramycin inhalation powder (TIP) can reduce the amount of Burkholderia Cepacia Complex (BCC) species - type of bacteria, in the sputum of cystic fibrosis patient.

Timeline

Start
2014-09
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule Inhaled